Biogen Inc.
- BIIB
- NASDAQ
- Drug manufacturers
- Multiple Sclerosis Drugs
- Neurology/Neuroscience
$234.68
Today +0.87%Quote Oct 19, 2026, 07:39 PM UTC
+6.21%over the last month
Max drawdown −4.5%From 1-month high −1.1%3 months +16.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Biogen
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA.
Where the money comes from
Q2 2026 revenue $2.74B
- MS Product Revenues$963.3M35.2%
- TYSABRI product$450.8M16.5%
- SPINRAZA$401.9M14.7%
- Fumarate$287.4M10.5%
- Interferon$225.1M8.2%
- Other / not reported$407.5M14.9%
Sector
Healthcare
Industry
Drug manufacturers
Exchange
NASDAQ
Employees
7,500
Market value
$34.67B
Quote Oct 19
Floor
$230.56
1.8% below price
Resistance
$235.42
0.3% above price
Price vs analyst targets
49 analysts
Lowest target
$175.00Highest target
$300.00
$175.00Highest target
$300.00
- Price $234.68
- Average target $245.88
- Analysts' target range
Analysts' average target sits about 5% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BIIBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free